drugset / Trial / NCT01099579

PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)

NCT01099579

Phase 3 Completed 82 enrolled Bristol-Myers Squibb
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether atazanavir powder combined with ritonavir is safe and well tolerated and produces appropriate drug exposure in children ≥3 months to \<6 years of age.

Timeline

Start
2010-10-13
Primary completion
2012-10-04
Completion
2017-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 150 mg Oral
Subject Atazanavir Other / unclassified 200 mg Oral
Subject Atazanavir Other / unclassified 250 mg Oral
Subject Atazanavir Other / unclassified 300 mg Oral
Background Ritonavir Other / unclassified 80 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral